A research team has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell ...

Should you invest in Bicara Therapeutics Inc? Click for more on BCAX's promising cancer treatment, but proceed with caution ...

“We know [immunotherapy] can work in untreated or previously treated but ... in a review of the topic at the recent World Conference on Lung Cancer. But how does a large molecule, like pembrolizumab, ...

Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...

Researchers have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could overcome that resistance. The study used a ...

Brian Beers is a digital editor, writer, Emmy-nominated producer, and content expert with 15+ years of experience writing about corporate finance & accounting, fundamental analysis, and investing ...

ALPMF's expanding lineup of cancer drugs, including zolbetuximab, positions them for substantial market growth and potential appreciation.

The brain receives and processes those messages, then decides how to react and tells the body what to do. It all happens in a nanosecond. Although research has come a long way, we still don’t ...

Adding pembrolizumab to adjuvant chemotherapy in the first-line setting improved disease-free survival (DFS) in patients with high-risk endometrial cancer who have mismatch repair–deficient ...

All you have to do is obtain a configuration file and activate it on the device. Providers generally refer to this as an eSIM profile and offer it as a QR code that you can scan to download.

The Phase 3 clinical trial showed that enfortumab vedotin in combination with pembrolizumab nearly doubled ... today is a tremendous amount of hard work and collaboration between the medical ...

Study Rundown: Pembrolizumab combined with neoadjuvant chemotherapy has shown promise in improving event-free survival among patients with early-stage non-small-cell lung cancer (NSCLC). The ...